Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
The company expects meaningful revenue contribution from this long-term agreement
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
CRL shall invest another Rs. 200 crore for creation of additional beds
Subscribe To Our Newsletter & Stay Updated